Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019

THOUSAND OAKS, Calif., June 2, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from Phase 1 studies evaluating investigational bispecific T cell engager (BiTE®) molecules were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in...

from PR Newswire: http://bit.ly/2Kmp5UC